Device Trial Radar · NCT01073566
Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections
Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- Calibra Medical, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Nancy Bohannon, MD, Med. Corp.; Henry Ford Health System; Northwestern University; University of Texas Southwestern Medical Center; International Diabetes Center at Park Nicollet
- First posted
- Feb 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate that Finesse, for prandial insulin bolusing when used in conjunction with basal insulin, achieves equivalent glycemic control when compared to multiple daily injections and to evaluate its preference.
Conditions
- Diabetes Mellitus
Interventions
FinesseDevice
Finesse Insulin Delivery Patch
Pen/Syringe (Usual injection device)Device
Pen/Syringe
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Daily Blood GlucoseTime frame: 6 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
California Pacific Medical Center
San Francisco, California
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.